Abetimus

Identification

Name
Abetimus
Accession Number
DB06662
Type
Biotech
Groups
Investigational
Biologic Classification
Nucleic Acid Based Therapies
Oligonucleotides
Description

Abetimus is an immunosuppressant developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Abetimus sodiumF5Y7739G6U169147-32-4Not applicable
International/Other Brands
Riquent
Categories
UNII
P3UVQ22SHK
CAS number
167362-48-3

Pharmacology

Indication

Investigated for use/treatment in kidney disease and systemic lupus erythematosus.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Abetimus.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Abetimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Abetimus.
ActeosideThe risk or severity of adverse effects can be increased when Abetimus is combined with Acteoside.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Abetimus.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Abetimus.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Abetimus.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Abetimus.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Abetimus.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Abetimus.
Food Interactions
Not Available

References

General References
  1. Authors unspecified: Abetimus: Abetimus sodium, LJP 394. BioDrugs. 2003;17(3):212-5. [PubMed:12749759]
  2. Wallace DJ: Clinical and pharmacological experience with LJP-394. Expert Opin Investig Drugs. 2001 Jan;10(1):111-7. [PubMed:11116284]
External Links
Wikipedia
Abetimus
ATC Codes
L04AA22 — Abetimus

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnDiagnosticSystemic Lupus Erythematosus (SLE)1
3CompletedTreatmentAutoimmune Diseases / Immunologic Diseases / Lupus Glomerulonephritis / Nephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
3TerminatedTreatmentLupus Erythematosus, Systemic / Nephritis, Lupus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:46 / Updated on November 02, 2018 09:01